Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site (Q33911465)

30 July 2017

title

Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site (English)

1 reference

30 July 2017

7

Alexander M M Eggermont

1 reference

30 July 2017

6

Johannes H W de Wilt

1 reference

30 July 2017

8

Cornelis Verhoef

1 reference

30 July 2017

5

Albertus N van Geel

1 reference

30 July 2017

Sebastiaan P Prens

1

1 reference

30 July 2017

Augustinus P T van der Ploeg

series ordinal

2

1 reference

30 July 2017

Alexander C J van Akkooi

series ordinal

3

1 reference

30 July 2017

Cornelis A G M van Montfort

series ordinal

4

1 reference

30 July 2017

language of work or name

1 reference

25 May 2011

1 reference

Annals of Surgical Oncology

30 July 2017

published in

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

13

1 reference

30 July 2017

page(s)

3586-3592

1 reference

The Evolution of Melanoma Diagnosis: 25 Years Beyond the ABCDs

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Prognostic factors after cervical lymph node dissection for cutaneous melanoma metastases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222814

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1245%2FS10434-011-1801-5

Melanoma without a detectable primary site with metastases to lymph nodes

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1245%2FS10434-011-1801-5

Epidemiology of extracutaneous melanoma in the Netherlands

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1245%2FS10434-011-1801-5

Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group

21 January 2018

1 reference

12 December 2020

Metastatic melanoma to lymph nodes in patients with unknown primary sites

1 reference

12 December 2020

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses

1 reference

12 December 2020

Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma

1 reference

12 December 2020

Dermoscopy of fully regressive cutaneous melanoma

1 reference

12 December 2020

2010 TNM staging system for cutaneous melanoma...and beyond

1 reference

12 December 2020

In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients

1 reference

12 December 2020

Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma

1 reference

12 December 2020

10.1245/S10434-011-1801-5

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference